Purpose

This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical activity for patients with bladder cancer that has not reached the muscle wall of the bladder (non-muscle invasive). For people who are not physically active, previous studies have shown that increasing step counts can reduce incidence of death, reduce frailty, and reduce healthcare costs. The ExerciseRx app tracks adherence to home exercise, adapts step count goals based on the patient's progress, and provides encouraging feedback and motivation from the healthcare team. Additional features include activity summaries, progress towards current goal, nudges, helpful facts about the benefits of activity, and ideas for how to incorporate daily movement. A home-based PAP using the ExerciseRx app may work better in increasing physical activity among patients with non-muscle invasive bladder cancer compared to a health education only group.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults (age >= 18 years) - Prior diagnosis of non-muscle invasive bladder cancer (NMIBC), currently on surveillance or receiving maintenance intravesical therapy (including intravesical chemotherapy, immunotherapy) - Classified as insufficiently active on the Physical Activity as a Vital Sign (PAVS) assessment - Has an Android or Apple Smartphone/Tablet - Ambulatory - English-speaking - Willing and able to participate in study activities and sign the informed consent form

Exclusion Criteria

  • Severe cognitive or memory impairment/dementia precluding ability to follow instructions or participate in survey assessments - Inability to read or understand English - Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria to run the ExerciseRx app - Not receiving treatment at University of Washington (UW) - Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility - Inability/Unwillingness to participate in a personalized exercise program - Current diagnosis with muscle-invasive or metastatic bladder cancer - Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using the ExerciseRx app - Participation in a clinical trial that does not permit enrollment in the EMPOWER trial

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Supportive Care
Masking
Single (Outcomes Assessor)
Masking Description
Study statistician will be blinded to group assignment

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Group I: Health Education Group (HEG)
Patients receive recommendations from their physicians to continue their usual physical activity as tolerated, receive a FitBit® to wear continuously throughout the study, with the ExerciseRx app locked to the baseline home screen, and receive an educational pamphlet describing physical activity goals in line with NCCN Survivorship for Healthy Living Guidelines.
  • Other: Best Practice
    Given instruction to continue physical activity as usual
    Other names:
    • standard of care
  • Other: Internet-Based Intervention
    Given access to the ExerciseRx app locked to the baseline home screen
  • Other: Health Telemonitoring
    Given a FitBit® to wear continuously
  • Other: Educational Intervention
    Given NCCN Survivorship for Healthy Living Guidelines pamphlet
  • Other: Questionnaire Administration
    Ancillary studies
  • Other: Interview
    Ancillary studies
  • Other: Electronic Health Record Review
    Ancillary studies
Experimental
Group II: Physical Activity Program (PAP) intervention
Patients complete home exercise sessions given via the ExerciseRx app over 20-30 minutes 4 times per week for 12 weeks and receive daily step count goals. Patients also receive a FitBit® to wear continuously throughout the study, and are given access to view their step counts via the ExerciseRx app, and receive an educational pamphlet as in Group I.
  • Other: Internet-Based Intervention
    Given access to the ExerciseRx app
  • Other: Exercise Intervention
    Complete home exercise sessions
  • Other: Health Telemonitoring
    Given a FitBit® to wear continuously
  • Other: Educational Intervention
    Given NCCN Survivorship for Healthy Living Guidelines pamphlet
  • Other: Questionnaire Administration
    Ancillary studies
  • Other: Interview
    Ancillary studies
  • Other: Electronic Health Record Review
    Ancillary studies

Recruiting Locations

Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington 98109
Contact:
Sarah Psutka, MD, MSc
206-210-4040
spsutka@uw.edu

More Details

Status
Recruiting
Sponsor
University of Washington

Study Contact

Sarah Psutka, MD, MSc
206-210-4040
spsutka@uw.edu

Detailed Description

OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I (Health Education Group, HEG): Patients receive recommendations from their physicians and an educational pamphlet describing physical activity goals in line with National Comprehensive Cancer Network (NCCN) Survivorship for Healthy Living Guidelines. They receive a FitBit® to wear continuously throughout the study, with the ExerciseRx app locked to the baseline home screen. GROUP II (PAP INTERVENTION): Patients complete home exercise sessions given via the ExerciseRx app over 20-30 minutes 4 times per week for 12 weeks and receive personalized daily step count goals that gradually increase over the study period. Patients also receive a FitBit® to wear continuously throughout the study, are given access to features of the ExerciseRx app (step count goals, home exercise videos), and receive an educational pamphlet as in Group I. After completion of the study intervention, patients are followed up at 4 weeks.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.